Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

NCT03026166 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03026166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03026166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Terminated
Start date
March 30, 2017
Completion date
July 3, 2019
Enrollment
42 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer